Hola me recomendasteis melatonina defender para un ictus, lo he consultado al Doctor Devesa y dice que es poco la dosis de 5mg el dice que mejor 50mg media hora antes de irse a dormir ¿ teneis de esa dosis?la farmacia de Valencia no la tienen ademas me ofrece la de melatonina noche
Pregunta puesta por victoria

Es una dosis nada habitual 50 mg. La melatonina es efectiva para el sueño en 0,5 mg las dosis habituales de entre 1-5 mg abarcan las necesidades habituales, superando en mucho la dosis farmacológica de melatonina. No es una dosis que comercializamos porque es excepcional. Nuestro complemento DEFENDER de 5 mg permite tomar hasta 3 comprimidos (15 mg) que aconsejamos en casos excepcionales pero en ningún caso 10 comprimidos para esos 50 mg. Sobre las dosis en esos casos realmente vamos sin conocimiento siguiendo el principio de que al no ser tóxica cuanto más antioxidante mejor, no hay datos, ni estudios, por lo cual entiendo es el criterio que utiliza Devesa. En lo referente al tiempo de la toma dependerá del suplemento de melatonina en cuestión, si es fast o retard. Lamento pues no poder facilitarle melatonina de ese gramaje

Respuesta por: Melatonina.it

Le adjunto las conclusiones de un estudio sobre el tema Victoria para apoyar mis palabras:
"Effects of melatonin in experimental stroke
models in acute, sub-acute, and chronic stages"Neuropsychiatric Disease and Treatment 2009
Efectivamente habla de dodis muy elevadas de 300 mg en ELA y de estudios con resultados prometedores en mejora neurobiológicas en Alzheimer utilizando dosis de 3-6 mg. Es todo un campo nuevo y se va por ensayo y error, pero con la seguridad de su atoxicidad y de que mal en ningún caso hará. le dejo las conclusiones del artículo que está en inglés:
Concluding remarks
In addition to its initial protective effects as a free radical
scavenger and antioxidant, abundant studies showed that
melatonin has multifaceted properties acting against cerebral
hypoxia/ischemia and its protection could be long-lasting
over months. The outcome measurements in these animal
studies, including infarction volume, edema, BBB integrity,
electrophysiology, and motor and sensory behaviors, are
useful translational parameters and applicable to clinical
assessments for the prognosis of stroke patients. Further
studies are recommended to evaluate effects of melatonin on
stroke animals with other co-morbidity since the physiological
background of animals might affect the effectiveness of a
treatment and determines whether clinical trials will succeed.
Interestingly, gender difference has also been noted in our
studies where female animals require lower dose of melatonin
to confer neuroprotection after MCAO compared to male
counterparts (unpublished observation). It has been shown
that estradiol signifi cantly reduces damage caused by cerebral
ischemia.54,55 It is possible that estrogen and melatonin have
synergistic effects and play important roles in determining the
severity of cerebral ischemia. This hypothesis requires further
investigation. Moreover, neurogenic effects of melatonin
remain an important fi eld to explore since it provides important
information whether long-term use of melatonin will be
helpful for stroke patients.
As melatonin has long been used for ameliorating sleep
disturbance and shows no toxicity on humans, clinical
trials assessing effects of melatonin on other neurological
disorders, including amyotrophic lateral sclerosis (ALS)
and Alzheimer’s disease, have been conducted. In a
group of 31 patients with sporadic ALS, high-dose of
melatonin (300 mg/day) given rectally was well tolerated
up to two years of observation and it reduced the level of
circulating serum protein carbonyls, which is indicative of
oxidative stress.56 Another double-blind study was conducted
on 20 patients with Alzheimer’s type of dementia where
melatonin (3 mg) was given continuously for four weeks,
and results showed that melatonin treatment improved sleep
time and night activity as well as cognitive and noncognitive
functions.57 Similar results were reported by a different group
on a larger size of group (45 patients) with longer treatment
paradigm (four month period with 6 mg/day).58 Data from
these clinical trials suggest that administering melatonin is
safe and improves neurological functions. In our perspective,
administrating melatonin should be done in a timely
manner as soon as cerebral ischemia occurs and ideally within
three hours.59 With its potent antioxidant capacity and other
anti-apoptosis and anti-infl ammatory effects, melatonin could
be therapeutically useful in a clinical setting for patients
suffering from cerebral ischemia.


Respuesta por: Melatonina.it